InvestorsObserver
×
News Home

Do Analysts Expect Armata Pharmaceuticals Inc (ARMP) Stock to Rise?

Monday, September 28, 2020 03:34 PM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Expect Armata Pharmaceuticals Inc (ARMP) Stock to Rise?

Wall Street is positive on Armata Pharmaceuticals Inc (ARMP). On average, analysts give ARMP a Strong Buy rating. The average price target is $7.25, which means analysts expect the stock to rise by 141.67% over the next twelve months.

That average ranking earns ARMP an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating ARMP a Strong Buy today. Find out what this means to you and get the rest of the rankings on ARMP!

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.

InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Armata Pharmaceuticals Inc Stock Today?

Armata Pharmaceuticals Inc (ARMP) stock has fallen -4.01% while the S&P 500 is higher by 1.69% as of 2:45 PM on Monday, Sep 28. ARMP has fallen -$0.12 from the previous closing price of $3.12 on volume of 25,684 shares. Over the past year the S&P 500 has gained 12.68% while ARMP has fallen -18.92%. ARMP lost -$1.95 per share the over the last 12 months.

Click Here to get the full report on Armata Pharmaceuticals Inc (ARMP) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App